The Role of ALPK1 in Inhibiting Hepatitis B Virus Replication Facilitates the Identification of ALPK1 P660L Variant for Predicting Response to Pegylated Interferon α Therapy
The Journal of Infectious Diseases · 2023
DOI: 10.1093/infdis/jiad065 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infectious Diseases, 2023. Verfasst von Shuang Lou und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Guangdong Institute of Liver Disease…. Hauptthemen laut MEDLINE: Hepatitis B virus, Hepatitis B, Chronic. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Gefördert von: National Key Research and Development Program of China, General Programs from the National Natural Science Foundation of China, Local Innovative and Research Teams Project of Guangdong Pearl River Talents Program.
Abstract (Originalsprache)
Background
Alpha kinase 1 (ALPK1) agonist has recently been reported to demonstrate anti–hepatitis B virus (HBV) efficacy via activating NF-κB signaling, which is crucial for maximizing interferon (IFN) responses. Here, we investigated the impact of ALPK1 on HBV replication and explored ALPK1 variants for predicting the response to pegylated IFN-α (PegIFN-α) treatment.
Methods
The potential anti-HBV effect of ALPK1 was evaluated in HBV-integrated and HBV-infected hepatoma cells. The potentially functional genetic variants of ALPK1 were screened out, and their correlations with PegIFN-α treatment response were assessed in 945 hepatitis B e antigen (HBeAg)–positive patients with chronic hepatitis B (CHB).
Results
We revealed that ALPK1 inhibited HBV replication in hepatocytes via activating the JAK-STAT pathway. ALPK1 overexpression improved the anti-HBV effect of IFN-α in cell models. A missense variant, rs35389530 (P660L), of ALPK1 was strongly associated with combined response (CR; namely, HBeAg seroconversion and HBV DNA level <3.3log10 IU/mL) to PegIFN-α treatment in patients with CHB (P = 2.12 × 10−6). Moreover, a polygenic score integrating ALPK1_rs35389530 and 2 additional genetic variants was further significantly associated with CR (Ptrend = 9.28 × 10−7), hepatitis B surface antigen (HBsAg) level (Ptrend = .0002), and HBsAg loss (Ptrend = .025).
Conclusions
The anti-HBV effects of ALPK1 through activating JAK-STAT pathway provides a new perspective for CHB therapy. ALPK1_rs35389530 and polygenic score are potential biomarkers to predict PegIFN-α treatment response and may be used for optimizing CHB treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Organ Failure Research, Guangdong Provincial Key Laboratory of Viral Hepatitis Research, Guangdong Institute of Liver Diseases, Department of Infectious Diseases and Hepatology Unit, Nanfang Hosp…
- The Key Laboratory of Molecular Pathology (Hepatic Diseases) of Guangxi, Department of Pathology, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, Guangxi, China.
- Food Safety and Health Research Center, School of Public Health, Southern Medical University, Guangzhou, China.
- School of Public Health (Shenzhen), Sun Yat-sen University, Shenzhen, China.
ORCID-Profile: Shuang Lou, De-Ke Jiang
Förderung
- National Key Research and Development Program of China
- General Programs from the National Natural Science Foundation of China
- Local Innovative and Research Teams Project of Guangdong Pearl River Talents Program
- General Program from the Natural Science Foundation of Guangdong Province
- Innovative Research Team
- Nanfang Hospital
- Southern Medical University
Zitieren
APA
Lou, S., Wang, J., Chen, J., Xie, H., Chen, H., Zhou, B., Zhang, B., Hou, J., & Jiang, D. K. (2023). The Role of ALPK1 in Inhibiting Hepatitis B Virus Replication Facilitates the Identification of ALPK1 P660L Variant for Predicting Response to Pegylated Interferon α Therapy. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jiad065
Vancouver
Lou S, Wang J, Chen J, Xie H, Chen H, Zhou B, et al. The Role of ALPK1 in Inhibiting Hepatitis B Virus Replication Facilitates the Identification of ALPK1 P660L Variant for Predicting Response to Pegylated Interferon α Therapy. The Journal of Infectious Diseases. 2023. doi:10.1093/infdis/jiad065
BibTeX
@article{Lou2023,
author = {Lou, Shuang and Wang, Jialin and Chen, Jiaxuan and Xie, Haisheng and Chen, Haitao and Zhou, Bin and Zhang, Bo and Hou, Jinlin and Jiang, De-Ke},
title = {The Role of ALPK1 in Inhibiting Hepatitis B Virus Replication Facilitates the Identification of ALPK1 P660L Variant for Predicting Response to Pegylated Interferon α Therapy},
journal = {The Journal of Infectious Diseases},
year = {2023},
doi = {10.1093/infdis/jiad065}
}
EUVIMED